Zobrazeno 1 - 10
of 1 126
pro vyhledávání: '"EGFR inhibitor"'
Autor:
O. I. Kit, I. P. Kodonidi, E. M. Frantsiyants, I. V. Kaplieva, A. A. Glushko, L. K. Trepitaki, E. I. Surikova, V. A. Bandovkina, Yu. A. Pogorelova, I. V. Neskubina, O. V. Bykadorova, E. V. Serdyukova
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 11, Iss 3, Pp 54-64 (2024)
Purpose of the study. Preclinical study in experiment of antitumor efficacy of a new substance synthesized on the basis of pyrimidin-4-one derivative.Materials and methods. The sodium salt of 4-{2-[2-[2-(4-hydroxy-3-methoxyphenyl)-vinyl]-6-ethyl-4-ox
Externí odkaz:
https://doaj.org/article/4b51c4950fcd4ca4825e526a17a86a60
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Objective To investigate the impact of response to induction chemotherapy (IC) on survival outcomes in patients with locally advanced nasopharyngeal carcinoma (LANPC) and evaluate the efficacy of adding nimotuzumab to concurrent chemoradioth
Externí odkaz:
https://doaj.org/article/d78bc0a7ab534d4ca7077f79dc46f43f
Publikováno v:
Case Reports in Dermatology, Vol 16, Iss 1, Pp 133-139 (2024)
Introduction: The development of new and changing melanocytic lesions has been increasingly reported as an adverse dermatologic toxicity of BRAF inhibitor therapy. Melanocytic lesions and melanomas induced by BRAF inhibitor therapy that lack BRAF V60
Externí odkaz:
https://doaj.org/article/8d855a20e7da4480b0241ec7c5505142
Autor:
Hanne Marte Nymoen, Tine Norman Alver, Henrik Horndalsveen, Hanne Astrid Eide, Maria Moksnes Bjaanæs, Odd Terje Brustugun, Bjørn Henning Grønberg, Vilde Drageset Haakensen, Åslaug Helland
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundRadiotherapy (RT) can be used to reduce symptoms and maintain open airways for patients with non-small cell lung cancer when systemic treatment is not sufficient. For some patients, tumor control is not achieved due to radioresistance. Conc
Externí odkaz:
https://doaj.org/article/e8ccea5765124b9cb6e2d11e1fe3772e
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 3 (2024)
Externí odkaz:
https://doaj.org/article/288b9e3b4ba74b7997157386821cbccf
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 167, Iss , Pp 115491- (2023)
The Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for EGFR-mutated NSCLC. However, long-term clinical treatment often leads to acquired drug resistance, making NSCLC refractory. Therefor
Externí odkaz:
https://doaj.org/article/b69f72a89b054a1a9b7c741a77a00c94
Autor:
Amany Belal, Nagwa M. Abdel Gawad, Ahmed B. M. Mehany, Mohammed A. S. Abourehab, Hazem Elkady, Ahmed A. Al‐Karmalawy, Ahmed S. Ismael
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 1884-1902 (2022)
A new series of 1H-pyrrole (6a–c, 8a–c), pyrrolo[3,2-d]pyrimidines (9a–c) and pyrrolo[3,2-e][1, 4]diazepines (11a–c) were designed and synthesised. These compounds were designed to have the essential pharmacophoric features of EGFR Inhibitors
Externí odkaz:
https://doaj.org/article/d0010d6e90f24c7cabc2f9be034a65f9
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Many researchers are attempting to identify drugs that can be repurposed as effective therapies for Alzheimer’s disease (AD). Several recent studies have highlighted epidermal growth factor receptor (EGFR) inhibitors approved for use as anti-cancer
Externí odkaz:
https://doaj.org/article/f5cb5373c5ea476d9310c1cec7a15f04
Publikováno v:
Al-Mustansiriyah Journal of Pharmaceutical Sciences, Vol 23, Iss 3 (2023)
New pyridine derivatives of nabumetone containing 2-amino 3-cyano moieties were synthesized and aimed to introduce new EGFR kinase inhibitors through two methods either by synthesis of chalcone derivatives initially (1a-d) followed by reacting it
Externí odkaz:
https://doaj.org/article/6dcd95c0835043aaa07b7c04384f17de
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Colorectal cancer results in the deaths of hundreds of thousands of patients worldwide each year, with incidence expected to rise over the next two decades. In the metastatic setting, cytotoxic therapy options remain limited, which is reflected in th
Externí odkaz:
https://doaj.org/article/21ed1bae8eb840abb7dbee940bfbb246